Vertex Pharmaceuticals (VRTX) insider trading

By person

37 insiders · 1,875 transactions

31.8×

Reshma Kewalramani holds 31.8 times base salary in stock. $51.01M of shares against $1.60M in salary for 2025.

Salary from the company's own proxy. The shares are what Reshma Kewalramani last reported holding, valued at $519.00, the price Common Stock was last bought or sold at on the open market here, on 2 Jul 2026.

Insider

Role

Bought

Sold

Net

Holding

Worth

Change

Jeffrey M Leiden

Executive Chairman

—

$498.46M (156) scheduled

−$498.46M

34,797

$18.06M

−86.8%

Amit Sachdev

EVP Chief Patient & Ext Af Off

—

$128.86M (187) scheduled

−$128.86M

66,512

$34.52M

−18.1%

Stuart A Arbuckle

EVP, COO

—

$114.36M (205) scheduled

−$114.36M

97,921

$50.82M

−39.4%

David Altshuler

EVP, Chief Scientific Officer

—

$88.19M (209) scheduled

−$88.19M

34,477

$17.89M

−64.0%

Reshma Kewalramani

CEO & President

$5.85M (4)

$80.66M (75) scheduled

−$74.81M

98,278

$51.01M

+964.3%

Ian F Smith

EVP, COO

—

$67.00M (49) scheduled

−$67.00M

46,699

$24.24M

−60.3%

Michael Parini

EVP, Chief Adm, Leg & BD Off

—

$45.43M (168) scheduled

−$45.43M

30,837

$16.00M

+109.9%

Paul M Silva

SVP & Chief Accounting Officer

—

$35.17M (136) scheduled

−$35.17M

9,884

$5.13M

−32.2%

Bruce I Sachs

Director

$8.18M (6)

$38.25M (28) scheduled

−$30.08M

39,000

$20.24M

+175.6%

Carmen Bozic

EVP and CMO

—

$30.00M (22) scheduled

−$30.00M

15,337

$7.96M

+631.4%

Jeffrey Chodakewitz

EVP

—

$27.57M (71) scheduled

−$27.57M

69,663

$36.16M

−38.1%

Charles F Wagner Jr

EVP, Co & Fo

—

$24.25M (48) scheduled

−$24.25M

47,042

$24.41M

+6,535%

Ourania Tatsis

EVP, Chief Reg. & Quality Off.

—

$21.35M (93) scheduled

−$21.35M

53,572

$27.80M

+529.0%

Yuchun Lee

Director

—

$18.69M (138) scheduled

−$18.69M

1,875

$973.13K

−52.9%

Margaret G McGlynn

Director

—

$14.52M (14) scheduled

−$14.52M

178

$92.38K

−95.7%

Terrence C Kearney

Director

—

$13.99M (7) scheduled

−$13.99M

6,536

$3.39M

+47.2%

Sangeeta N. Bhatia

Director

—

$12.67M (63) scheduled

−$12.67M

4,924

$2.56M

+67.4%

Edward Morrow Atkinson III

EVP, Chief Technical Ops. Off.

—

$11.60M (13) scheduled

−$11.60M

18,432

$9.57M

+32.8%

William D Young

Director

—

$10.94M (8) scheduled

−$10.94M

9,311

$4.83M

+216.6%

Bastiano Sanna

EVP, Cell & Genetic Therapies

—

$10.54M (63) scheduled

−$10.54M

32,038

$16.63M

+49.6%

Jonathan Biller

EVP and Chief Legal Officer

—

$7.81M (12) scheduled

−$7.81M

13,659

$7.09M

—

Duncan McKechnie

EVP, Chief Commercial Officer

—

$5.66M (5) scheduled

−$5.66M

11,001

$5.71M

−32.1%

Joshua S Boger

Director

—

$5.41M (33) scheduled

−$5.41M

284,088

$147.44M

+0.8%

Kristen Ambrose

SVP & Chief Accounting Officer

—

$4.93M (19) scheduled

−$4.93M

11,624

$6.03M

+733.9%

Joy Liu

EVP and Chief Legal Officer

—

$4.73M (31)

−$4.73M

19,131

$9.93M

−31.2%

Mark E. Bunnage

EVP, Chief Scientific Officer

—

$3.00M (5) scheduled

−$3.00M

7,284

$3.78M

−54.7%

Lloyd Carney

Director

—

$865.41K (3)

−$865.41K

6,315

$3.28M

—

Thomas Graney

Chief Financial Officer

—

$324.44K (2)

−$324.44K

12,430

$6.45M

+5,628%

Elaine Ullian

Director

—

12,195

$6.33M

+48.6%

Grunsven Jasper van

EVP, CP and NPPO

—

8,682

$4.51M

—

Alan M Garber

Director

—

7,344

$3.81M

—

Diana McKenzie

Director

—

2,378

$1.23M

—

Nancy Thornberry

Director

—

2,109

$1.09M

—

Suketu Upadhyay

Director

—

1,558

$808.60K

—

Jennifer Schneider

Director

—

1,394

$723.49K

—

Michel Lagarde

Director

—

1,132

$587.51K

—

Daniel J. Brennan

Director

—

795

$412.61K

—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.

Vertex Pharmaceuticals

What the insiders did Net selling

By person